BioNTech SE

BioNTech SE

WKN: A2PSR2 / ISIN: US09075V1026 / BNTX

Stock exchange: NASDAQ-GS
Sector: Health Care
Industry: Biotechnology: Biological Products

Baillie Gifford & Co.2.63%
PRIMECAP Management Co.1.77%
Jennison Associates LLC1.69%
Capital Research & Management Co. 1.21%
Shanghai Fosun Industry Investment Co., Ltd.0.65%
J.O. Hambro Capital Management Ltd.0.60%
BlackRock Fund Advisors0.59%
T. Rowe Price Associates, Inc.0.48%
Fidelity Management & Research Co. LLC0.48%
Coatue Management LLC0.43%

Biontech SE is a German biotechnology company that has been listed on the stock exchange since the end of 2019 and is based in Mainz. It has focused on the development and manufacture of active immunotherapies for a patient-specific approach to the treatment of cancer and other serious diseases, as well as coronavirus prevention. Biontech focuses on research into drugs based on mRNA. These can be used as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases. In addition, the company is active in researching programmable cell therapies (“Engineered Cell Therapy”), novel antibodies and low-molecular immunomodulators (“Small Molecules”) as treatment options for cancer.

Biontech is the first company to develop an mRNA-based human therapeutic agent for intramuscular administration, to bring individualized mRNA-based cancer immunotherapy into clinical studies and to establish its own manufacturing process for such a product candidate. From the beginning of 2020, Biontech developed the vaccine BNT162b2 against the human coronavirus SARS-CoV-2, which is manufactured in Pfizer plants for worldwide use. It is the company’s first product to be approved. According to the company, around 20 potential drugs are in the development phase.

The shares of Biontech have been publicly traded as American Depositary Receipts on the American stock exchange Nasdaq in the “Global Select Market” segment since October 10, 2019. In the run-up to the IPO and with effect from March 8, 2019, the company was converted from an AG to an SE. With a stake of over 50%, AT Impf, an investment company owned by Andreas and Thomas Strüngmann, is the largest single shareholder. Other institutional investors associated with the members of the management board and the supervisory board are Medine, MIG Verwaltung and FMR. Overall, the companies of these committee members hold almost 72% of the shares in Biontech. In August 2021, the market value was more than $ 100 billion.